Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Gains from Sales and Divestitures (2018 - 2025)

Sutro Biopharma's Gains from Sales and Divestitures history spans 8 years, with the latest figure at $252107.0 for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 85.13% to $252107.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $252107.0, a 85.13% decrease, with the full-year FY2025 number at $252107.0, down 85.13% from a year prior.
  • Gains from Sales and Divestitures hit $252107.0 in Q4 2025 for Sutro Biopharma, down from $2.3 million in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for STRO hit a ceiling of $2.3 million in Q3 2025 and a floor of $147349.0 in Q1 2021.
  • Historically, Gains from Sales and Divestitures has averaged $936361.2 across 5 years, with a median of $849019.0 in 2023.
  • Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 265.86% in 2021 and later tumbled 85.13% in 2025.
  • Tracing STRO's Gains from Sales and Divestitures over 5 years: stood at $238724.0 in 2021, then soared by 159.99% to $620647.0 in 2022, then soared by 86.2% to $1.2 million in 2023, then soared by 46.68% to $1.7 million in 2024, then tumbled by 85.13% to $252107.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for STRO at $252107.0 in Q4 2025, $2.3 million in Q3 2025, and $2.0 million in Q2 2025.